Avalon Pharmaceuticals
(AVRX) 0.00

19 Firstfield Road, Gaithersburg, MD 20878

Avalon Pharmaceuticals is discovering novel therapeutics against new and unknown drug targets by screening large libraries of small molecule chemicals for their effect on proprietary drug activity markers in multi-parameter disease model systems. This approach permits the screening of drug effects against many different targets in parallel without the need for detailed information about each target. Ý The drug discovery technologies developed by the company's scientist permits it to go beyond the current serial target based approaches to drug discovery and to discover new therapies much faster than conventional target based screening. Ý At present Avalon's technology is customized for the discovery of small molecule anti-cancer drugs. Avalon's novel drug discovery paradigm is expected to generate a new class of anti-cancer drugs with minimal side effects, extended survival and improved quality of life.

CEL-SCI Corporation
(CVM) 0.49

8229 Boone Blvd, Suite 802, Vienna, VA 22182

CEL-SCI Corporation was formed in 1983. CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The Company’s core capabilities include drug discovery, research, development and manufacturing of complex biological substances.

Celera - An Applera Corp Business
(CRA) 7.00

1401 Harbor Bay Parkway, Alameda CA 94502-7099 45 West Gude Drive, Rockville, MD 20850

Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.

Celsion Corporation
(CLSN) 3.20

10220-L Old Columbia Road, Columbia, MD 21046-1705

Celsion is dedicated to applying its proprietary focused heat technology to the development and commercialization of treatments for cancer and other diseases.Ý It is currently in late stage clinical development of innovative medical devices to treat both Benign Prostatic Hyperplasia (BPH), a prostate condition common in men over age 55, and breast cancer and is working with Duke University and Memorial Sloan-Kettering on the development of new heat-activated drugs and gene therapies.Ý

Digene

1201 Clopper Road, Gaithersburg, MD 20878

A leader in molecular diagnostics, Digene develops, manufactures and markets proprietary DNA and RNA tests focused on women's cancers and infectious diseases. The company's flagship product, The Digene® HPV Test* (DNAwithPap® Test), is the only FDA–approved test for the human papillomavirus (HPV), the primary cause of cervical cancer. Rapidly emerging as a standard of practice in cervical cancer screening, the HPV test aids healthcare professionals in identifying women who are most at risk of having or developing cervical cancer, which today is the world's second–most–common type of cancer affecting women. Digene's product portfolio also includes DNA tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses.

Emergent BioSolutions

2273 Research Boulevard, Suite 400, Rockville, MD 20850

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, our biodefense product portfolio includes a next generation anthrax vaccine program, which includes a product candidate in Phase I clinical development, and a botulism program with multiple product candidates in preclinical development. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our commercial product portfolio includes a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, both of which are in Phase II clinical development, a group B streptococcus vaccine candidate in Phase I clinical development and two vaccine candidates in preclinical development.

EntreMed Inc
(ENMD) 3.02

9640 Medical Center Drive, Rockville, MD 20850

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2, as well as new chemical entities associated with multi-kinase inhibition and HDAC inhibition, important targets in the treatment of oncology.

ExonHit Therapeutics

26 rue Brunel, F-75017 Paris - FRANCE Avenel Business Park, 217 Perry Parkway, Gaithersburg, MD 20877

ExonHit Therapeutics is a world-leading company in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. ExonHit's proprietary gene profiling technology DATAS™ is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company's strategy is to leverage on this valuable biological information in the fields of drug discovery, diagnostics and biochips.

Gene Logic Inc
*SERVICE*
(ORXE.PK) 0.35

50 West Watkins Mill Road, Gaithersburg, MD 20878

Gene Logic aims to be the drug development partner of choice for the pharmaceutical and biotechnology industries by providing a unique portfolio of drug discovery and development solutions. Our capabilities span the drug development pipeline and address some of the most important issues in drug development today - productivity, safety, and enhancing late-stage pipelines.

GenVec Inc
(GNVC) 0.46

65 West Watkins Mill Road, Gaithersburg, MD 20878

GenVec is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. Our lead product, TNFerade™, is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma, and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu and foot and mouth disease.

Human Genome Sciences Inc
(HGSI) 29.95

14200 Shady Grove Road, Rockville, MD 20850

Human Genome Sciences is a biopharmaceutical company with a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. Additional products are in clinical development by companies with which we are collaborating. Our mission is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody products.

Insmed
(INSM) 0.69

8720 Stony Point Parkway, Suite 200, Richmond, VA 23235

Insmed is engaged in the development and commercialization of drugs to treat patients with metabolic diseases that currently have limited treatment options. The company’s lead product, IPLEXTM, approved by the FDA in December 2005, is a composition of recombinant human IGF-1 and IGFbinding protein 3. IPLEXTM is now being studied as a treatment for several serious medical conditions, including two neuromuscular disorders, Myotonic Muscular Dystrophy (MMD) and ALS (Lou Gehrig’s Disease); HIV- Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP). Insmed is also developing novel products for the treatment of cancer. INSM-18 and rhIGFBP-3 are promising potential novel treatments for a variety of cancer types. Preclinical models demonstrate that both treatments interact with the IGF system to reduce tumor growth.

Intracel

93 Monocacy Blvd., Unit A8, Frederick, MD 21701

INTRACEL is developing and commercializing cancer vaccines and immunotherapeutic products for cancer and infectious diseases. The company has built a large portfolio of product candidates. Most advanced of which, OncoVAX , is a vaccine for Stage II colon cancer patients and is currently being marketed and provided on a commercial basis in the Netherlands. Late-Stage product candidates include: KLH (Keyhole Limpet Hemocyanin) for advanced bladder cancer and OncoVAX for Stage III colon cancer patients, which are both in Phase III development. INTRACEL has a number of fully human monoclonal antibodies in earlier stages of development to treat respiratory syncytial virus (RSV), major hospital infections and autoimmune disorders.

Macrogenics, Inc.

1500 East Gude Drive, Rockville, MD 20850

MacroGenics, Inc. is developing immune-based products including monoclonal antibodies to treat patients with cancer, autoimmune disorders, allergy, or infectious diseases and vaccines to prevent infections in healthy individuals.

Martek Biosciences Corp
(MATK) 22.31

6480 Dobbin Road, Columbia, MD 21045 PO Box 5000, 1416 N. Williamsburg County Hwy, Kingstree, SC 29556

Martek Biosciences Corporation is a leading innovator in the development of nutritional products that promote health and wellness through every stage of life. Martek has become a leader in fermentation technology and is an innovator in the research and development of products derived from microalgae. Martek has developed and patented two fermentable strains of microalgae which produce oils rich in docosahexaenoic acid, DHA. A similar patented process was developed for a fungus that produces an oil rich in arachidonic acid, ARA. Both DHA and ARA are important nutrients for optimal infant development, while DHA has health benefits that extend throughout life.

MaxCyte

22 Firstfield Road, Suite 250, Gaithersburg, MD 20878

MaxCyte is a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates. Programs in development are based on MaxCyte's platform technology which breaks down the barriers to ex vivo cell loading and the manufacture of viral vectors. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable technology to collaborators who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic manufacturing. Partners are currently working to develop therapeutics for pulmonary disease, congenital heart disease and cancer.

Medgenics

8000 Towers Crescent Dr., Suite 1300, Vienna, VA 22182 12 Hanapach St., P.O. Box 6314, Karmiel, 21653 Israel

Medgenics’ breakthrough technology promises a safe, single treatment that replaces months of injections, and their undesirable side effects. Producing and delivering therapeutic proteins right under the patient’s skin, this patented platform technology offers a novel and superior form of protein therapy. Long-acting, low-cost and efficient, Medgenics technology offers benefits to patients, physicians and payers alike. The company has demonstrated proof of principle in clinical trials delivering erythropoietin (EPO) to anemic patients.

MedImmune, Inc.

One MedImmune Way, Gaithersburg, MD 20878

The company is focused on the areas of infectious diseases, cancer and inflammatory diseases. The company has three marketed products and an advancing pipeline of promising candidates, all designed to treat or prevent a number of debilitating or life-threatening diseases.

Nabi Biopharmaceuticals
(NABI) 4.83

5800 Park of Commerce Blvd., N.W., Boca Raton, FL 33487 12276 Wilkins Avenue, Rockville, MD 20852

Nabi Biopharmaceuticals is focused on developing and marketing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. We are a fully-integrated biopharmaceutical company with our own facilities and employees to develop products (R&D); test, process and utilize antibodies collected at our antibody collection centers; manufacture products; and market and sell products.

Novavax
(NVAX) 2.27

9920 Belward Campus Drive, Rockville, MD 20850

Novavax Inc. is committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu. We have validated our approach in animals and are moving toward clinical testing.

Novoste Corporation

P.O. Box 315, Springfield, VA 22150

Novoste Corporation develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy - radiation therapy delivered inside a blood vessel to prevent its reclosure (restenosis) following balloon angioplasty and other catheter-based interventional procedures. The Novoste™ Beta-Cath™ System is commercially available in the United States, as well as in the European Union, Canada, and several other countries. The Beta-Cath™ System is primarily used to treat patients suffering from “in-stent” restenosis, a condition in which coronary stents become blocked with new tissue growth.

Omnia Biologics
*SERVICE*

12115-D Parklawn Dr., Rockville, MD 20852

Omnia Biologics provides customized manufacturing and process development solutions for the development of vaccines, gene therapeutics, and biodefense products. Our small-scale BSL-3 production facility (operating under cGMP) along with an expandable facility options enable us to handle a wide variety of products and offer complementary services.

Osiris Therapeutics, Inc.
(OSIR) 6.67

2001 Aliceanna Street, Baltimore, MD 21231

Osiris Therapeutics is commercializing products from a readily available and non-controversial source – adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including autoimmune disorders, heart attacks and arthritis. Osiris’ technology is based on the pioneering work of Dr. Arnold Caplan and his colleagues at Case Western Reserve University. They showed that Mesenchymal Stem Cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat. Due to their cellular origin and phenotype, these cells do not provoke an immune response, allowing for the development of products derived from unrelated human donors.

Panacea Pharmaceuticals

207 Perry Parkway, Suite 2, Gaithersburg, MD 20877

Panacea's mission is to discover, develop and commercialize innovative therapeutic and diagnostic products. Our current product development focus is on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's Disease, and Parkinson's Disease.

Panacos
(PANC.PK) 0.01

134 Coolidge Avenue, Watertown, MA 02472 209 Perry Parkway, Suite 7 Gaithersburg, MD 20877

Panacos' scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Panacos merged with V.I. Technologies, Inc. (Vitex), a biotechnology company developing products designed to improve the safety of the world's blood supply. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development.

PharmAthene, Inc.

175 Admiral Cochrane Drive, Suite #101, Annapolis, MD 21401

The development of effective countermeasures to a range of potential biological and chemical weapons is PharmAthene’s primary objective.

Regenerx, Inc.

3 Bethesda Metro Center, Suite 630, Bethesda, MD 20814

RegeneRx’s novel technology platform utilizes Thymosin Beta 4 (Tß4), a synthetic copy of a naturally-occuring human peptide that plays a vital role in tissue regeneration. The Company is developing drug candidates in three principal areas: dermal, ophthalmic and cardiovascular wound healing.

Sequella, Inc.

9610 Medical Center Drive, Suite 200, Rockville, MD 20850

Sequella develops products to improve diagnosis and treatment of infectious diseases that pose serious risk to public health and have both significant market opportunities and clear commercialization pathways.

Synthetic Genomics

9601 Blackwell Road, Suite 200, Rockville, MD 20850 11149 North Torrey Pines Road, Suite 100, La Jolla, CA 92037

*Synthetic Genomics, Inc., was founded by Dr. J. Craig Venter.*
The company is developing novel genomic-driven strategies to address global energy and environmental challenges. Recent advances in the field of synthetic genomics present seemingly limitless applications that could revolutionize production of energy, chemicals and pharmaceuticals and enable carbon sequestration and environmental remediation. Given our team’s longstanding history of pioneering science, we are uniquely positioned to ignite a biological industrial revolution, and we are committed to unlocking the keys to a clean energy future through genomics.

United Therapeutics Corp
(UTHR) 48.54

1110 Spring St. Silver Spring, MD 20910 One Park Drive, Fourth Floor, Research Triangle Park, NC 27709 The Surrey Research Park, 26 - 28 Frederick Sanger Road, Guildford, Surrey GU2 7YD, UK

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine.